Exhibit 99.1

BOSTON (Dow Jones)--A lifetime without cavities after a painless, five-minute visit with the dentist probably sounds too good to be true.

But Oragenics Inc. (V.ORA) thinks its oral rinse can make that a reality.

At the root of the Alachua, Fla., company's product is a benign strain of Streptococcus Mutans, a bacterium that is a major culprit in cavities.

Strep M, as it's known among scientists, breaks down sugar into a lactic acid that helps it attach to the sides of teeth. Oragenics' genetically engineered version of Strep M is like a benevolent twin: it acts like Strep M except it doesn't turn sugar into lactic acid. Further, Oragenics' version overwhelms the bad version and takes over its space, denying its ability to create cavities.

"It is a very clever idea and there is evidence in the laboratory of it being successful and in cases with animals of it being successful," said Dr. Dennis Mangan, chief of the infectious diseases and immunity branch of the National Institute of Dental and Craniofacial Research, which is part of the National Institutes of Health. "So now the question is will it be able to do it in the oral cavity of humans."

That question likely won't stand too long, as Oragenics has just finished preclinical studies and recently submitted an investigational new drug application to the Food and Drug Administration.

"We're hoping to get a date to start human trials at the beginning of next year," said Dr. Jeffrey Hillman, a Harvard-trained microbiologist and dentist who founded Oragenics in 1996, after 25 years of research into the DNA technology that underlies the company's patented "replacement therapy."

Hillman said he envisions the final product for use in humans as a liquid that a dentist would spray on a patient's teeth. The whole procedure, which could be done on adults or children as young as two years old, would take little more than five minutes, concluding with the traditional rinse and spit, he said.

Then, in a delicious twist on typical dental care, the dentist would tell the patient to "go home and eat something sugary," because it helps Oragenics' strain of Strep M to colonize, Hillman said.

Hillman thinks the result might be lifelong cavity protection, with little or no risk of side effects because the product is a strain of bacteria that occurs naturally in the human body.

"If it does pan out then it would change greatly the way dentistry is practiced," said Dr. Kenneth Burrell, senior director for the American Dental Association's Council on Scientific Affairs.

But Burrell, who said he heard Dr. Hillman speak at a professional conference, says he'll await the completion of the FDA clinical trials before passing judgment.

Dr. Walter Bretz, PhD., a professor at the University of Pittsburgh's School of Dental Medicine and an oral microbiologist, who said he has seen a limited amount of data on Hillman's work, also lauds the effort but says it won't likely be a panacea for cavity prevention.